Health News (Reuters)

PTC Therapeutics Duchenne drug may work, data inconclusive: FDA panel

(Reuters) - PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects young boys, may work but the company will need to do more work to prove it, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

Psoriasis patients face increased risk of heart attacks and death

(Reuters Health) - People with psoriasis, a chronic inflammatory disease, may be more likely than others to experience heart attacks and strokes at least in part because inflammation damages their vascular system, a recent study suggests.

Washington state sues OxyContin maker Purdue Pharma

(Reuters) - Washington state on Thursday sued OxyContin maker Purdue Pharma LP, becoming the latest state or local government to file a lawsuit seeking to hold pharmaceutical companies accountable for a national opioid addiction epidemic.

A single genetic glitch may explain how Zika became so dangerous

CHICAGO (Reuters) - A single genetic change that occurred in 2013 may explain how Zika acquired the ability to attack fetal nerve cells, causing a severe birth defect in babies whose mothers were infected while pregnant, Chinese and U.S. researchers reported on Thursday.

AbbVie, Amgen settlement sets Humira U.S. biosimilar launch for 2023

(Reuters) - Amgen Inc has reached a settlement with AbbVie Inc that will delay the U.S. launch of Amgen's cheaper biosimilar version of AbbVie's cash cow, the blockbuster rheumatoid arthritis drug Humira, until Jan. 31, 2023, the companies said on Thursday.

Pages